Close

Human Genome (HGSI) Affirms New Albiglutide from Glaxo (GSK)

April 3, 2012 7:46 AM EDT
Human Genome (Nasdaq: HGSI) reports that GlaxoSmithKline (NYSE: GSK) issued an update on its Phase III of Albiglutide. For more color, click here.

Albiglutide was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.

All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA